TIGRIS

A clinical trial for septic shock with endotoxemia

ClinicalTrials.Gov: NCT03901807 • IDE# G090151

Dr. John Kellum, Chief Medical Officer
jkellum@spectraldx.com

Open-label confirmatory RCT of biomarker-guided blood purification in the US

Granted Medical Breakthrough Designation by FDA

35% Subject Enrollment Complete

Looking for Additional Sites!

Patient Selection

Septic Shock requiring Vasopressors

Organ Dysfunction
MODS >9 or SOFA >11

Endotoxin Activity
0.6-0.9

Randomization
2:1

Conventional Treatment and Monitoring ✚ Two 2hr Toraymyxin™ Hemoperfusion Treatments (In 24 Hours)	Conventional Treatment and Monitoring

Treatment

PMX Treatment Duration:
2 hours



Perfusion Rate:
80-120 ml/min

Monitors inlet and outlet pressures

Primary Objective

Patient mortality
at 28 days

Secondary Objectives

01 Change in Mean Arterial Pressure (MAP)

02 Change in vasopressor dose

03 Total duration of vasopressor use

04 Patient mortality at 14 days

05 Patient survival time from baseline

References

1. Endotoxemic Shock: A Molecular Phenotype in Sepsis. Nephron, Jul 2022. Pages 1-4. Kellum, J. A., Foster, D., & Walker, P. M.
2. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA, Volume 320, Oct 2018. Pages 1455-1463. Dellinger, R. P., Bagshaw, S. M., Antonelli, M., Foster, D. M., Klein, D. J., Marshall, J. C., Palevsky, P. M., Weisberg, L. S., Schorr, C. A., Trzeciak, S., Walker, P. M., & EUPHRATES Trial Investigators
3. Mechanisms of Organ Dysfunction in Sepsis. Critical care clinics, Volume 34, Jan 2018. Pages 63-80. Pool, R., Gomez, H., & Kellum, J. A.

THE 28TH INTERNATIONAL CONFERENCE ON
ADVANCES IN CRITICAL CARE NEPHROLOGY
AKI & CRRT 2023
MARCH 29 - APRIL 1 SAN DIEGO, CALIFORNIA